Shaalan Beg MD MBA FASCO (@ShaalanBeg) header
Shaalan Beg MD MBA FASCO (@ShaalanBeg) profile picture

Reimagining cancer clinical trials. Foodie, family guy, digital health. FCOI: https://nitter.cf/t.co/CtEt9hUUH9

Dallas, Texas
Joined February 2015
Photo by Shaalan Beg MD MBA FASCO (@ShaalanBeg)Photo by Shaalan Beg MD MBA FASCO (@ShaalanBeg)Photo by Shaalan Beg MD MBA FASCO (@ShaalanBeg)Photo by Shaalan Beg MD MBA FASCO (@ShaalanBeg)Photo by Shaalan Beg MD MBA FASCO (@ShaalanBeg)Photo by Shaalan Beg MD MBA FASCO (@ShaalanBeg)Photo by Shaalan Beg MD MBA FASCO (@ShaalanBeg)Photo by Shaalan Beg MD MBA FASCO (@ShaalanBeg)Photo by Shaalan Beg MD MBA FASCO (@ShaalanBeg)Photo by Shaalan Beg MD MBA FASCO (@ShaalanBeg)
Shaalan Beg MD MBA FASCO retweeted
Trastuzumab plus nivolumab with GemCis as 1L therapy for HER2-positive unresectable BTC: pls 1b/2 trial @NatureMedicine doi.org/10.1038/s41591-026-0… 👉ORR 55%, DCR 95% 👉mPFS 10.6 mo, mOS nr 🧐Promising, HERIZON BTC & DESTINY-BTC awaited
2
19
1
42
2,565
Shaalan Beg MD MBA FASCO retweeted
🚨⭐️Your Outlook email may not be working & your flight may be delayed ✈️ so you might have a few minutes to read our Perspective, just published hot off the press @Nature @Nature_NPJ 👉Open access, free for all to read - at least @X & internet are working :) #precisionmedicine #AI 👉"AI-based prediction of actionable genomic alterations from H&E-stained slides" 🔬 👉Tissue exhaustion & slow turnaround still keep patients from the right targeted therapy. Deep learning models can now predict actionable genomic alterations directly from routine H&E, and the prospective EAGLE (EGFR, NSCLC) and ANNAR (FGFR, urothelial) studies show this holds across diverse global cohorts. 👉Near-instant, non-destructive results let us triage patients for molecular testing or clinical trials at the time of diagnosis. Every lab in the world makes an H&E slide, and this puts molecular information within reach of all of them @OncoAlert @oncodaily nature.com/articles/s41698-0…
1
11
37
3,689
Shaalan Beg MD MBA FASCO retweeted
Great perspective from @PauloBergerot in @ASCO Daily News on a critical challenge in #ExerciseOncology: moving beyond the optimal exercise dose to interventions that are feasible, accessible, and sustainable in patients’ everyday lives #ASCOQLTY26 dailynews.ascopubs.org/do/ca…
2
10
3
33
2,936
Shaalan Beg MD MBA FASCO retweeted
Our atlas of young-onset CRC is finally out in @NatureMedicine! We found a unique biology in younger patients that may explain the aggressive nature of this disease. This was a monumental effort with colleagues at @MassGenBrigham and @broadinstitute. @DFarberYoungCRC
Researchers co-led by @KimmieNgMD of @DanaFarber and @DFarberYoungCRC created the largest single-cell atlas of colorectal cancer ever, identifying age-associated differences that may help research into why #colorectalcancer can be more aggressive in younger adults. ➡️bit.ly/4kmBFEl
8
42
3
171
15,119
Shaalan Beg MD MBA FASCO retweeted
ASCO Members! You now get full access to ASCO Meetings content 30 days post-meeting. Explore the latest science faster! View content from the 2026 ASCO Annual Meeting: bit.ly/4hXg1DS Coming soon: An AI-powered agent from ASCO & Google Cloud to simplify your research.
4
6
1,677
Shaalan Beg MD MBA FASCO retweeted
We are looking to hire post-doctoral fellows to work on somatic mosaicism, regeneration, and cancer development, please reach out to me if you are interested! @CRI_UTSW
14
3
18
3,862
Shaalan Beg MD MBA FASCO retweeted
Dr. @QasimHussainiMD giving an amazing discussion of two studies on #ExerciseOncology presented at @ASCO Quality Care Symposium this morning. asco.org/quality/program #ASCOQLTY26 @crisbergerot @PauloBergerot
11
1
19
1,575
Shaalan Beg MD MBA FASCO retweeted
Fantastic oral abstract discussion by Dr. @CharlesJiangMD at @ASCO Quality Care Symposium today! asco.org/quality/program?int… #ASCOQLTY26 @utswcancer @UTSWMedCenter
1
5
20
1,058
Hey, @TimothyJBrownMD, can an F-150 do this?
Tesla unveiled a redesigned Roadster equipped with thrusters that enable it to fly short distances, nearly nine years after it first showed a next-generation version of its electric sports car, and said it would start production in 2028 reut.rs/4zt7Q9A
1
1
2
1,520
Shaalan Beg MD MBA FASCO retweeted
Great to see work from @ASCO Quality Care Symposium simultaneously published in @JCO_ASCO today: “Effectiveness of a Multisite Oncology Financial Navigation Intervention: The Lessening the Impact of Financial Toxicity Clinical Trial.” ascopubs.org/doi/pdf/10.1200… #ASCOQLTY26
1
8
1
21
890
Geographical access to clinical trials remains the number one barrier to enrollment. Look forward to hearing how technology-enabled services are being used by sites to improve access to cancer trials. #ascoqlty26
1
1
1
5
630
Shaalan Beg MD MBA FASCO retweeted
Atezolizumab is now @FDA ✅ off #ATOMIC Ph III, adj mFOLFOX + Atezo vs. mFOLFOX in Stg III dMMR colon ca. - 3yr DFS 86.4% vs 76.6% (HR 0.50) - OS not mature - ⬆️ Gr4 neutropenia with Atezo. - How much is chemo benefitting? Role of NICHE2? - @ASCO Plenary! #gism #OncTwitter
2
19
36
3,124
Shaalan Beg MD MBA FASCO retweeted
How has teamwork transformed patient outcomes in your practice? Bring Dr. Elizabeth Mittendorf’s @ASCOPres theme—Intentional Teams. Exceptional Care.—to life on the #ASCO27 stage during the ASCO Voices session. 🎙️ Submit your audition by November 13: bit.ly/4ALUHts
1
7
15
4,515
Shaalan Beg MD MBA FASCO retweeted
Based off HER2CLIMB-05, Tucatinib is now @FDA ✅ as maintenance for HER2+ mBC, PhIII, THP —> HP +/-Tucatinib - Improved PFS in all subsets - mPFS: 24.9mos vs. 16.3mos (HR: 0.64) - ⬆️ AEs with Tucatinib (LFTs & diarrhea) #BreastCancer #bcsm #OncTwitter
4
21
2
39
8,256
Shaalan Beg MD MBA FASCO retweeted
We have 3 Anti-Her2 options today for Upper GI adenocarcinoma. Here is the table outlining dose, common toxicities, and clinical pearls in managing these AEs that we touched on during our #ToxCheck discussion with @ShrutiPatelMD & @Sam_Cytryn #MedTwitter #MedX #OncTwitter
Tox-Check: Anti-Her2 drugs in Upper GI (Esophageal, GE Junction, and Gastric Adenocarcinoma) w/ @ShrutiPatelMD & @Sam_Cytryn ✅ Trastuzumab ✅ Zanidatamab ✅ TDXd Full 🗣️: ⭐️ oncbrothers.com/toxcheck-her… ⭐️ “Oncology Brothers” podcast #OncTwitter @OncoAlert @OncUpdates #gism
1
10
34
4,082
Shaalan Beg MD MBA FASCO retweeted
Getting ready to present the phase II GRECO-2 trial Tuesday at #ASTRO26. Can’t stop thinking of you, @TaniguchiMD. There is no way I can represent the purple hair like you did, but I’ll do my best to represent the SOD story. Missing you, brother. RIP.
1
7
1
63
5,674
Shaalan Beg MD MBA FASCO retweeted
⭐️🚨Just published 👉🏼Pleased to share our standout new review 👉🏼published in @TheLancet @eClinicalMed 👉🏼led by 3 amazing rising stars ⭐️ @JiaJennyLiu @niamhjcoleman @JulianaRBeal 👉🏼“Tumour‑agnostic immunotherapy: aligning biological rationale, biomarker precision, and real‑world implementation.” 👉🏼 Tumour‑agnostic immunotherapy has reshaped precision oncology by showing that, in selected settings, treatment benefit can be driven by a shared biological state rather than anatomical origin. The clearest example: MSI‑H/dMMR cancers, where durable responses span diverse malignancies. ⭐️Such a delight to work with & mentor this dream team 👉🏼their clarity, rigor, and vision shine through every section 🎯🔥 @OncoAlert @oncodaily @OncBrothers thelancet.com/journals/eclin…
4
21
52
2,880
Shaalan Beg MD MBA FASCO retweeted
🚨Another big win for #precisionmedicine 🚨👉🏼Today the FDA approved lirafugratinib for FGFR2‑rearranged cholangiocarcinoma. ⭐️I still remember the first patient in the universe we enrolled on the trial during the peak of the pandemic. Three days in - I called the amazing Ben- the then CMO of @Relay_Tx “Your drug is working, working too good. We need to work on the right dosing & get it right for patients. I think this baby will graduate someday.” That day is today 🙌🏼 Thankful to all patients who volunteered & the amazing teams that got this to finish line 🙏🏽 !!! @OncoAlert @oncodaily @OncBrothers @ElizSMcKenna @matthewherper @curecc @Aiims1742 @MiteshBorad @AliSchram 👉🏼Link to FDA approval fda.gov/drugs/resources-info… 👉🏼Link to @CD_AACR @AACR bench to bedside publication aacrjournals.org/cancerdisco…
📣Super thrilled to share our paper on RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations & Resistance Mutations, published in @CD_AACR ! 👉🏼Huge thanks to team at Cancer Discovery & @AACR for making the front page & the entire paper so visually appealing  👏🏼#PrecisionMedicine 🧬🎯#cancerresearch @OncoAlert @ElizSMcKenna @Relay_Tx @TaliLev123 👉🏼Free Link: tinyurl.com/yfffae53
2
27
2
62
8,340
We are witnessing the most exciting period of drug development in oncology. There's a lot of discussion on the FDA's Accelerated Approval pathway. Who should be eligible to receive AA? When should approvals be withdrawn? We tackle this #onlyoncologistsinthebuilding 🔎🔎🕵🏻‍♂️
2
3
13
706